Sydney R Rooney, Elaine L Shelton, Ida Aka, Christian M Shaffer, Ronald I Clyman, John M Dagle, Kelli Ryckman, Tamorah R Lewis, Jeff Reese, Sara L Van Driest, Prince J Kannankeril
{"title":"<i>CYP2C9*2</i> is associated with indomethacin treatment failure for patent ductus arteriosus.","authors":"Sydney R Rooney, Elaine L Shelton, Ida Aka, Christian M Shaffer, Ronald I Clyman, John M Dagle, Kelli Ryckman, Tamorah R Lewis, Jeff Reese, Sara L Van Driest, Prince J Kannankeril","doi":"10.2217/pgs-2019-0079","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). <b>Patients & Methods:</b> This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. <b>Results:</b> In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and <i>CYP2C9*2</i> (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. <b>Conclusion:</b> Age, surfactant use, and <i>CYP2C9*2</i> influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.</p>","PeriodicalId":78777,"journal":{"name":"The Milbank Memorial Fund quarterly","volume":"36 1 1","pages":"939-946"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817966/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Milbank Memorial Fund quarterly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2019-0079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). Patients & Methods: This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. Results: In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and CYP2C9*2 (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. Conclusion: Age, surfactant use, and CYP2C9*2 influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
